Antifungals: what's in the pipeline

Curr Opin Microbiol. 2001 Oct;4(5):540-5. doi: 10.1016/s1369-5274(00)00248-4.

Abstract

The therapeutic landscape for mycotic infections is shifting. New generation azoles that are active against clinically relevant, drug-resistant fungal pathogens have improved bioavailability, half-lives and safety profiles. Acylated cyclic peptide inhibitors of beta(1,3)glucan synthesis with origins as fungal metabolites provide an alternative and highly-selective mode of action, targeting cell-wall biogenesis in important pathogens such as Candida and Aspergillus species. The development, in each structural class, of compounds that have advanced to late-stage clinical trials is summarized in this review.

Publication types

  • Review

MeSH terms

  • Antifungal Agents / chemistry*
  • Antifungal Agents / pharmacology*
  • Aspergillosis / microbiology
  • Aspergillus / drug effects*
  • Candida / drug effects*
  • Candidiasis / microbiology
  • Cell Wall / drug effects
  • Cell Wall / metabolism
  • Clinical Trials as Topic
  • Glucans / antagonists & inhibitors*
  • Humans
  • Research
  • beta-Glucans*

Substances

  • Antifungal Agents
  • Glucans
  • beta-Glucans
  • beta-1,3-glucan